Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 2511 to 2520 of 2582 total matches.

Rabies Vaccine

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 1990  (Issue 834)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Human rabies continues to be rare in the USA, but animal rabies is becoming more common. An animal epizootic in the mid-Atlantic states, involving especially raccoons, has recently spread into the northeastern states.
Med Lett Drugs Ther. 1990 Dec 28;32(834):117-8 |  Show IntroductionHide Introduction

Laser Coronary Angioplasty

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 1991  (Issue 836)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Percutaneous transluminal coronary angioplasty (PTCA), in which a balloon catheter distends the vessel at the site of obstruction (Medical Letter, 25:97, 1983), is now an established therapeutic option for treatment of patients with coronary artery disease, especially those with single-vessel disease. Major problems related to PTCA include acute occlusion during the procedure (usually caused by dissection), restenosis at the site of angioplasty, and inability to treat complete occlusions and long or ostial lesions. Some cardiologists have tried using lasers during PTCA to deal with these...
Med Lett Drugs Ther. 1991 Jan 25;33(836):7-8 |  Show IntroductionHide Introduction

Zinc for the Common Cold

   
The Medical Letter on Drugs and Therapeutics • Jan 31, 1997  (Issue 993)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Results of a recent study suggested that zinc gluconate may be effective in treating the common cold (SB Mossad et al, Ann Intern Med, 125:81, July 15, 1996). Zinc gluconate lozenges, sometimes combined with vitamin C or other ingredients, are available in pharmacies and health food stores throughout the USA.
Med Lett Drugs Ther. 1997 Jan 31;39(993):9-10 |  Show IntroductionHide Introduction

Sucralose--A New Artificial Sweetener

   
The Medical Letter on Drugs and Therapeutics • Jul 03, 1998  (Issue 1030)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Sucralose (Splenda - McNeil Specialty) has been approved by the FDA for use as a nonnutritive sweetener in beverages, baked goods and other foods, and as a tabletop sugar substitute (Fed Reg, 63:16417, April 3, 1998). Other non-caloric sweeteners available in the USA include saccharin (Sweet'n Low, and others), aspartame (NutraSweet, Equal) and acesulfame potassium (Sunette - Medical Letter, 30:116, 1988).
Med Lett Drugs Ther. 1998 Jul 3;40(1030):67-8 |  Show IntroductionHide Introduction

The Atkins Diet

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2000  (Issue 1080)
The Medical Letter  On Drugs and Therapeutics Published by The Medical Letter, Inc. • 1000 Main ...
Nearly 30 years after the first publication of Dr. Atkins' Diet Revolution promoting a high-protein, extremely low-carbohydrate diet, patients once again are asking their physicians about the Atkins diet.
Med Lett Drugs Ther. 2000 Jun 12;42(1080):52 |  Show IntroductionHide Introduction

Aztreonam for Inhalation Solution (Cayston) for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 2010  (Issue 1344)
The Medical Letter® On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
The antibiotic aztreonam is now available as an inhalation solution (Cayston – Gilead) to improve respiratory symptoms in cystic fibrosis (CF) patients ≥7 years old colonized with Pseudomonas aeruginosa. It is the second inhaled antibiotic to be FDA-approved for this indication in CF patients; the aminoglycoside tobramycin (Tobi) was the first. Inhaled antibiotics offer the advantage of high airway concentrations while minimizing systemic side effects.
Med Lett Drugs Ther. 2010 Aug 9;52(1344):63-4 |  Show IntroductionHide Introduction

A New Scorpion Antivenom

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012  (Issue 1393)
The Medical Letter® On Drugs and Therapeutics Volume 54 (Issue 1393) June 25, 2012 ...
Anascorp (Rare Disease Therapeutics), an intravenously administered antivenom derived from horse serum, has been approved by the FDA for treatment of clinical signs of scorpion envenomation.
Med Lett Drugs Ther. 2012 Jun 25;54(1393):51-2 |  Show IntroductionHide Introduction

Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 23, 2012  (Issue 1395)
The Medical Letter® On Drugs and Therapeutics Volume 54 (Issue 1395) July 23, 2012 ...
Pertuzumab (Perjeta – Roche/Genentech), a humanized monoclonal antibody, has been approved by the FDA for use in combination with trastuzumab (Herceptin) and docetaxel (Taxotere, and others) for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
Med Lett Drugs Ther. 2012 Jul 23;54(1395):59-60 |  Show IntroductionHide Introduction

Nutritional Supplements for Age-Related Macular Degeneration Revisited

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2013  (Issue 1419)
The Medical Letter® On Drugs and Therapeutics Volume 55 (Issue 1419) June 24, 2013 Published ...
The results of the Age-Related Eye Disease Study 2 (AREDS2) have now been published. The primary purpose of the study was to evaluate the efficacy and safety of the carotenoids lutein and zeaxanthin and the omega-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in reducing the risk of developing advanced age-related macular degeneration (AMD). A secondary goal was to test the effects of reducing the amount of zinc and eliminating beta carotene from the original AREDS formulation. Beta carotene has been shown to increase the risk of...
Med Lett Drugs Ther. 2013 Jun 24;55(1419):50-1 |  Show IntroductionHide Introduction

Belotero Balance for Wrinkles and Folds

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2013  (Issue 1428)
The Medical Letter® On Drugs and Therapeutics Volume 55 (Issue 1428) October 28, 2013 Published ...
Belotero Balance (Merz), an injectable hyaluronic acid dermal filler, has been approved by the FDA for temporary correction of moderate-to-severe facial wrinkles and folds. Several other hyaluronic acid products are also available for this indication (e.g., Restylane, Perlane, Juvéderm). They have supplanted bovine collagen products, which persist for a shorter time and cause more allergic reactions.
Med Lett Drugs Ther. 2013 Oct 28;55(1428):86-7 |  Show IntroductionHide Introduction